Therapies for active rheumatoid arthritis after methotrexate failure

New England Journal of Medicine

Volumn 369, Issue 4, 2013, Pages 307-318

  O'Dell, James R ^a   Mikuls, Ted R ^a   Taylor, Thomas H ^b   Ahluwalia, Vandana ^c   Brophy, Mary ^f,g   Warren, Stuart R ⁱ   Lew, Robert A ^f,h   Cannella, Amy C ^a   Kunkel, Gary ^j   Phibbs, Ciaran S ^k,l   Anis, Aslam H ^d   Leatherman, Sarah ^f   Keystone, Edward ^e  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b White River Junction VA Medical Center ^*  (Canada)

^c University of Queensland   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

^f Massachusetts Veterans Epidemiology and Research Information Center   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h BOSTON UNIVERSITY   (United States)

ⁱ University of New Mexico   (United States)

^j UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^k VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^l STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; HYDROXYCHLOROQUINE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ABNORMAL LABORATORY RESULT; ACR20; ACR50; ACR70; ADULT; ARTICLE; BONE EROSION; CLINICAL DISEASE ACTIVITY INDEX; COMBINATION CHEMOTHERAPY; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DAS28; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EYE DISEASE; FEMALE; FUNCTIONAL STATUS; GASTROINTESTINAL DISEASE; HEALTH ASSESSMENT QUESTIONNAIRE; HEART DISEASE; HUMAN; INFECTION; INFESTATION; INJECTION SITE REACTION; JOINT SPACE NARROWING; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MODIFIED SHARP SCORE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL SYSTEM PARAMETERS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SKIN DISEASE; THORAX DISEASE; UNSPECIFIED SIDE EFFECT; URINARY TRACT DISEASE; VASCULAR DISEASE;

EID: 84880753128     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1303006     Document Type: Article

References (36)

1. McInnes IB, O'Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010;69:1898-906. [Erratum, Ann Rheum Dis 2011;70:399.]
2. O'Dell JR. Treatment of rheumatoid arthritis. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, O'Dell JR, eds. Kelley's textbook of rheumatology. 9th ed. Philadelphia: Elsevier, 2013:1137-60.
3. Singh JA, Furst DE, Bharat A, et al. Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39.
4. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75. [Erratum, Ann Rheum Dis 2011;70:1519.]
5. Vermeer M, Kuper HH, Hoekstra M, et al. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum 2011;63: 2865-72.
6. Moreland LW, O'Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the Treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 2012;64: 2824-35.
7. Ozminkowski RJ, Burton WN, Goetzel RZ, Maclean R, Wang S. The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits. J Occup Environ Med 2006;48:135-48. (Pubitemid 43237945)
8. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90. (Pubitemid 41612204)
9. van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009;374:459-66.
10. Lipsky PE, van der Heijde DMFM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602. (Pubitemid 32162982)
11. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37. (Pubitemid 43122183)
12. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9. (Pubitemid 29063266)
13. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-fourweek, multicenter, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24. (Pubitemid 34214243)
14. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human antitumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45. [Erratum, Arthritis Rheum 2003;48:855.] (Pubitemid 36091645)
15. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-76. (Pubitemid 46768126)
16. Emery P, Fleischmann R, Filipowicz- Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54:1390-400.
17. Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964-75. [Erratum, Arthritis Rheum 2010;62:3518.] (Pubitemid 351563997)
18. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80.
19. Keystone E, van der Heijde D, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58: 3319-29. [Erratum, Arthritis Rheum 2009; 60:1249.]
20. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103.
21. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-41.
22. O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334: 1287-91. (Pubitemid 26138009)
23. O'Dell JR, Leff R, Paulsen G, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1164-70. (Pubitemid 34525821)
24. Kremer MJ, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:726-33. (Pubitemid 35265316)
25. Lehman AJ, Esdaile JM, Klinkhoff AV, Grant E, Fitzgerald A, Canvin J. A 48- week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Arthritis Rheum 2005;52:1360-70. (Pubitemid 40663926)
26. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
27. Maska L, Anderson J, Michaud K. Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL). Arthritis Care Res (Hoboken) 2011;63:Suppl 11:S4-S13.
28. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified Disease Activity Scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
29. van Gestel AM, Prevoo MLL, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/ International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39:34-40. (Pubitemid 26036375)
30. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999;26: 743-5.
31. Felson DT, Anderson JJ, Boers M, et al. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
32. Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7: R796-R806.
33. Chow S-C, Wang H, Shao J. Sample size calculations in clinical research. 2nd ed. Boca Raton, FL: Chapman & Hall/CRC, 2008.
34. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-87. (Pubitemid 30452465)
35. American College of Rheumatology Rheumatoid Arthritis Clinical Trial Investigators Ad Hoc Task Force. American College of Rheumatology Clinical Trial Priorities and Design Conference, July 22-23, 2010. Arthritis Rheum 2011;63:2151-6.
36. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9. (Pubitemid 38942816) Research and Development